Full Text View
Tabular View
Study Results
Related Studies
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
This study has been completed.
Study NCT00332241   Information provided by Bristol-Myers Squibb
First Received: May 31, 2006   Last Updated: June 3, 2009   History of Changes
Study Type: Interventional
Study Design: Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment
Condition: Autistic Disorder
Interventions: Drug: Aripiprazole
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo oral placebo once daily (QD)
Aripiprazole oral aripiprazole 2 to 15 mg QD

Participant Flow:   Overall Study
  Placebo Aripiprazole
STARTED   51     47  
COMPLETED   36     39  
NOT COMPLETED   15     8  
      Lack of Efficacy               6                 1  
      Adverse Event               3                 5  
      Withdrawal by Subject               2                 1  
      Lost to Follow-up               4                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Placebo oral placebo once daily (QD)
Aripiprazole oral aripiprazole 2 to 15 mg QD

Baseline Measures
  Placebo Aripiprazole Total
Number of Participants  
[units: participants]
51 47 98
Age, Customized  
[units: participants]
     
6 to 12 years 46 37 83
13 to 17 years 5 10 15
Gender  
[units: participants]
     
Female 7 5 12
Male 44 42 86
Race/Ethnicity, Customized  
[units: participants]
     
Asian 0 2 2
Native Hawaiian or Other Pacific Islander 0 1 1
Black or African American 7 11 18
White 41 32 73
Other 3 1 4
Race/Ethnicity, Customized  
[units: participants]
     
Hispanic/Latino 8 6 14
Not Hispanic/Latino 43 41 84
Weight Group  
[units: Participants]
     
<40 kilograms 32 26 58
≥40 kilograms 19 21 40
Body Mass Index  
[units: kg/cm2]
Mean ± Standard Deviation
19.96 ± 5.392 21.08 ± 5.394 20.50 ± 5.395
Height  
[units: centimeters]
Mean ± Standard Deviation
138.6 ± 14.7 140.9 ± 18.80 139.7 ± 16.74
Weight  
[units: kilograms]
Mean ± Standard Deviation
40.6 ± 18.92 43.9 ± 19.15 42.2 ± 19.01



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score   [ Week 8 ]

2.  Secondary:   Mean Clinical Global Impressions Improvement Scale (CGI-I) Score   [ Week 8 ]

3.  Secondary:   Number of Participants With Response at Week 8   [ Week 8 ]

4.  Secondary:   Mean Change (Week 8 – Baseline) in the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Compulsion Scale Only)   [ Week 8 ]

5.  Secondary:   Mean Change (Week 8 - Baseline) in the Other ABC Subscale Scores   [ Week 8 ]

6.  Secondary:   Mean Change (Week 8 - Baseline) in CGI-Severity (CGI-S)   [ Week 8 ]

7.  Secondary:   Summary of Safety   [ continuous throughout the study ]

8.  Secondary:   Change From Baseline in Body Weight   [ Week 8 ]


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Show More Information